lactobacillus delbrueckii

Cell therapyexperimental

Lactobacillus bulgaricus is the main bacterium used for the production of yogurt. It also plays a crucial role in the ripening of some cheeses, as well as in other processes involving naturally fermented products. It is defined as homofermentive lactic acid bacteria due to lactic acid being the single end product of its carbohydrate digestion. It is also considered a probiotic. — Wikipedia

Clinical trial activity

120 trials · 148 clinical orgs · 0 marketing orgs

Phase 1
12
Phase 2
27
Phase 3
23
Phase 4
13

Earliest trial started Dec 1, 2003 (NCT00159523)

Timeline

2000s

  1. Jan 1, 2003

    Earliest Phase 3 Sponsor(trial)

  2. Jan 1, 2004

    Earliest Phase 1 Sponsor(trial)

  3. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • microbiotaTissue restoration

    microbiota tissue restoration

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • lactobacillus delbruckii lactis
  • lactobacillus delbrueckii
  • lactobacillus delbrueckii subsp. bulgaricus
  • lactobacillus delbrueckii subspecies bulgaricus lb-51
  • probiotic
  • vsl #3
  • vsl#3

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06658821N/ADec 1, 2024Chung Shan Medical University, Synbio Tech
NCT05467605N/AJul 31, 2022Cairo University
NCT05805488N/AOct 1, 2021China Medical University, TCI Co., Ltd.
NCT05007470N/ASep 1, 2021University of California, Los Angeles
NCT04506385Early Phase 1 (Phase 1)Apr 20, 2020Probiotical S.p.A., University of Florence
NCT04167995Early Phase 1 (Phase 1)Nov 9, 2019Ain Shams University
NCT04572932N/AMay 1, 2019Ain Shams University
NCT03940612N/AMay 1, 2019Synbio Tech, University of Science Malaysia
NCT04053790Phase 4Jan 15, 2019National Autonomous University of Mexico
NCT03586622N/ASep 1, 2018Calpro AS, Colitis-Crohn Foreningen, Ferring, Genetic Analysis, North Zealands University Hospital, Statens Serum Institut, University of Copenhagen
NCT03801655N/AAug 15, 2018University of Oxford
NCT03682094Early Phase 1 (Phase 1)Aug 13, 2018University of Wisconsin
NCT03511365Phase 1/Phase 2 (Phase 2)May 15, 2018Northwell Health
NCT03327051Phase 4Nov 30, 2017Stanford University
NCT03196453N/AAug 1, 2017University of Turku
NCT03165747Phase 2Jul 5, 2017Emory University
NCT03092427N/AMay 1, 2017University of Paris
NCT03052179N/AMay 1, 2017University of London
NCT03415711N/AApr 28, 2017Universita' Cattolica del Sacro Cuore, VSL Pharmaceuticals
NCT02568891Phase 2Jan 1, 2017Medical University of Graz
Showing 20 of 120 trials
Page 1 / 6

Organizations

Research & Development (148)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
VSL PharmaceuticalsFor profit7342004
NestleFor profit5522007
DaniscoFor profit4332011
University of CopenhagenAcademic/Hospital4412009
University of LondonAcademic/Hospital4432007
University of WisconsinAcademic/Hospital4432008
Ain Shams UniversityAcademic/Hospital2222019
All India Institute of Medical SciencesAcademic/Hospital2112007
Biopolis S.L.For profit2212015
CD Pharma India Pvt. Ltd.For profit2212009
China Medical UniversityAcademic/Hospital2112011
Chr HansenFor profit2012009
Clinical Research Associates of TidewaterFor profit2012011
FerringFor profit2022010
Hebrew UniversityAcademic/Hospital2222004
Indian Council of Medical ResearchAcademic/Hospital2022009
Korott, S.L.For profit2012015
Medical University of GrazAcademic/Hospital2212016
National University of SingaporeAcademic/Hospital2222006
Next Gen Pharma India Pvt. Ltd.For profit2212015
148 organizations
Page 1 / 8